784ODocetaxel (D) with androgen suppression (AS) for...

Annals of Oncology 2017 / 09 Vol. 28; Iss. suppl_5

784ODocetaxel (D) with androgen suppression (AS) for high-risk localized prostate cancer (HrPC) patients (pts) who relapsed PSA after radical prostatectomy (RP) and/or radiotherapy (RT): A randomized phase III trial

Oudard, S., Latorzeff, I., Caty, A., Miglianico, L., Sevin, E., Hardy Bessard, A-C., Delva, R., Rolland, F., Chevreau, C., Priou, F., Beuzeboc, P., Gravis, G., Linassier, C., Gomez, P., Voog, E., Chin
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
28
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx370.001
Date:
September, 2017
File:
PDF, 92 KB
english, 2017
Conversion to is in progress
Conversion to is failed